Diabetes Medicine May Help Reduce Blood Sugar More Quickly

Type 2 diabetes occurs when the body cannot use insulin effectively. Insulin is the hormone that moves sugar from the bloodstream into cells.

When that process breaks down, blood sugar can stay elevated for long stretches of time. Over time, this can harm the heart, kidneys, nerves, eyes, and blood vessels.

Keeping blood sugar under control is a key part of diabetes treatment. Care may include dietary changes, physical activity, and medications that help lower glucose levels. For people who are overweight, weight loss can also improve blood sugar control and lower some health risks.

A study led by Dr. Adie Viljoen at East and North Hertfordshire NHS Trust looked at how quickly the diabetes drug tirzepatide helped patients reach blood sugar and weight targets. The results were published in Diabetes Therapy. The analysis compared tirzepatide with semaglutide and the long-acting insulin degludec.

Tirzepatide is an injectable treatment for type 2 diabetes. It works on two hormone systems, GIP and GLP-1, which help regulate blood sugar after meals and affect appetite. Semaglutide acts mainly through GLP-1, while insulin degludec provides long-acting insulin support to help control glucose.

The researchers measured how long it took people to reach common treatment goals. Blood sugar control was assessed using HbA1c, a test that reflects average blood sugar over about the previous two to three months. Lower HbA1c levels usually indicate better long-term control.

People taking tirzepatide reached an HbA1c below 7% in roughly eight weeks. Those using semaglutide or insulin degludec needed about 12 weeks to reach the same target. For the stricter HbA1c goal of 6.5% or lower, tirzepatide users reached it in about 12 weeks.

By contrast, semaglutide users took around 16 weeks to reach that tighter blood sugar target, while people on insulin degludec needed about 24 weeks. The findings suggest tirzepatide may help some patients achieve meaningful blood sugar improvements relatively quickly.

The team also examined weight loss. People receiving 10 mg and 15 mg doses of tirzepatide reached at least 5% weight loss in about 12 weeks. In the analysis, those taking semaglutide needed about 24 weeks to reach the same milestone.

Weight loss can be especially helpful for many people with type 2 diabetes because it may improve the body's response to insulin. Even modest reductions in weight can bring health benefits. Still, the amount of weight lost and the pace of improvement can differ widely from person to person.

Quicker results may help motivate some patients to stay with treatment and maintain healthy lifestyle changes. But speed is only one factor in choosing a diabetes medication. Doctors also weigh side effects, other medical conditions, treatment goals, cost, availability, and patient preference.

Tirzepatide can cause side effects, especially digestive problems such as nausea, diarrhea, reduced appetite, and vomiting. It is not appropriate for every patient and should be used under medical supervision. People should not change diabetes treatment based on study results without speaking with a healthcare professional.

The study adds to evidence that tirzepatide can be an effective option for lowering blood sugar and supporting weight loss in type 2 diabetes. Even so, reaching a target more quickly does not necessarily mean a drug is the best long-term choice for every patient. Ongoing research and individualized care remain important for balancing benefits, risks, and lasting diabetes control.